The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…
Search results for: hospital
Optical Workings: Specialists Must Communicate to Treat Eye Disease
In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…
Trainees Discuss Pros, Cons of Rheumatology Residency Rotation
One day not too long ago, right smack in the middle of Thanksgiving and Christmas, I was sitting at the roundtable of our conference room, also known as the solarium due to its sunny disposition. The spirit was high, and we all felt like we could bring some joy to the clinic that day. I…
How Tuberculosis Has Shaped Medicine and Society
Pathologists are legendary for blending their work product with the culinary arts. Through the years, their use of delectable foods as descriptors has created a clever way to indelibly link in the minds of clinicians the histopathologic observations of disease with an assortment of these tasty foods: There is the depiction of an apple green…
Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab
Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…
Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models
The work of health policy reform is a marathon, not a sprint. The ACR is encouraged by the forward progress being made in collaboration with the American Medical Association and other physician-led organizations within the Healthcare Leaders for Accountable Innovation in Medicare and Medicaid coalition (known as the AIM coalition) to advocate for physicians’ ability…
Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis
Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…
5 Easy-to-Implement Quality Improvement Projects for Rheumatology Practices
Quality assurance and quality improvement (QA/QI) work makes sense to focus on. However, finding the time and resources for QI projects is not always easy. Until now, the business case for QI in rheumatology practice has not always been clear. However, this is changing with implementation of the Medicare Access and CHIP Reauthorization Act (MACRA)…
Medical Schools Address Bias, Diversity, Inclusion in Variety of Ways
“What are you?” A faculty member at the University of California, San Francisco (UCSF) School of Medicine posed this question to a resident while attending rounds. Both were portraying a scene involving micro-aggression during Differences Matter, a three-day orientation for first-year medical students. On the program’s first day, students are introduced to unconscious bias and…
FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
The FDA has approved a new formulation of methotrexate designed as an oral solution for pediatric patients. The agency has also recently introduced age restrictions for codeine and tramadol for children under age 12, citing their risks for slowed or difficult breathing and death…
- « Previous Page
- 1
- …
- 188
- 189
- 190
- 191
- 192
- …
- 328
- Next Page »